FDA warns Germany-based USApeptide.com that it sells unapproved and misbranded semaglutide and tirzepatide drugs to U.S. consumers online.
What happened
FDA reviewed the website www.usapeptide.com and found semaglutide and tirzepatide products offered for sale with claims that they are intended for human use, despite “research use only” disclaimers. FDA said the products are new drugs without approved applications and prescription drugs offered without a prescription. The letter also noted the products are intended for injection and the site sells bacteriostatic water and insulin syringes.
What FDA found
FDA says the semaglutide products are unapproved new drugs because no FDA-approved application is in effect for them.
FD&C Act sections 505(a) and 301(d) [21 U.S.C. §§ 355(a), 331(d)]FDA says the tirzepatide products are unapproved new drugs because no FDA-approved application is in effect for them.
FD&C Act sections 505(a) and 301(d) [21 U.S.C. §§ 355(a), 331(d)]FDA says the labeling lacks adequate directions for use, so the drugs are misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)] and section 301(a) [21 U.S.C. § 331(a)]FDA says offering prescription drugs without requiring a prescription misbrands them while held for sale.
FD&C Act sections 503(b)(1) and 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]FDA says website claims show the products are intended as drugs for human use despite “research use only” language.
FD&C Act section 201(g) [21 U.S.C. § 321(g)]FDA says the products are intended for injection, which can bypass natural defenses and pose serious infection risks.
What FDA wants
FDA asks USApeptide.com to stop offering any unapproved and misbranded drugs for sale to U.S. consumers. It also asks for a written response within 15 working days describing corrective steps and documentation, or an explanation for any delay.
Who should pay attention
- online sellers shipping drug products to U.S. consumers
- consumers and clinics buying GLP-1 products online
- companies handling semaglutide or tirzepatide products
This is a summary. Read the original letter on fda.gov.